Dynavax Technologies Stock Price, Forecast & Analysis (NASDAQ:DVAX)

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Dynavax Technologies Co. (NASDAQ:DVAX) issued its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by $0.10. The biopharmaceutical company earned $10.58 million during the quarter, compared to analysts' expectations of $10.31 million. Dynavax Technologies had a negative net margin of 519.95% and a negative return on equity of 399.60%. The company's revenue for the quarter was up 624.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.65) EPS. View Dynavax Technologies' Earnings History.

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Dynavax Technologies.

5 Wall Street analysts have issued 1 year price objectives for Dynavax Technologies' stock. Their forecasts range from $13.00 to $20.00. On average, they expect Dynavax Technologies' share price to reach $15.33 in the next twelve months. This suggests a possible upside of 172.8% from the stock's current price. View Analyst Price Targets for Dynavax Technologies.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dynavax Technologies.

Media headlines about DVAX stock have been trending very negative this week, InfoTrie reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Dynavax Technologies earned a daily sentiment score of -3.2 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Dynavax Technologies.

Some companies that are related to Dynavax Technologies include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Biogen (BIIB), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Array Biopharma (ARRY), United Continental (UAL), Kite Pharma (KITE), Cara Therapeutics (CARA) and Micron Technology (MU).

Dynavax Technologies' stock is owned by many different of institutional and retail investors. Top institutional investors include Chicago Capital LLC (6.72%), Rhumbline Advisers (0.15%), Gables Capital Management Inc. (0.10%), California Public Employees Retirement System (0.09%), Commonwealth Equity Services LLC (0.05%) and Ingalls & Snyder LLC (0.02%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Institutional Ownership Trends for Dynavax Technologies.

DVAX stock was acquired by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Ingalls & Snyder LLC, California Public Employees Retirement System, Rhumbline Advisers, Gables Capital Management Inc. and Commonwealth Equity Services LLC. View Insider Buying and Selling for Dynavax Technologies.

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DVAX stock can currently be purchased for approximately $5.62.

Dynavax Technologies has a market capitalization of $366.17 million and generates $8.20 million in revenue each year. The biopharmaceutical company earns $-158,900,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Dynavax Technologies employs 249 workers across the globe.View Additional Information About Dynavax Technologies.

The official website for Dynavax Technologies is http://www.dynavax.com/.

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]